232 related articles for article (PubMed ID: 21886780)
1. Hepcidin levels and their determinants in different types of myelodysplastic syndromes.
Santini V; Girelli D; Sanna A; Martinelli N; Duca L; Campostrini N; Cortelezzi A; Corbella M; Bosi A; Reda G; Olivieri O; Cappellini MD
PLoS One; 2011; 6(8):e23109. PubMed ID: 21886780
[TBL] [Abstract][Full Text] [Related]
2. [Detection of Hepcidin in transfusion dependent myelodysplastic syndrome patients and its clinical significance].
Qin Y; Liu H; Ruan S; Cai YF; You XF; Song GQ
Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):758-61. PubMed ID: 22339912
[TBL] [Abstract][Full Text] [Related]
3. The evaluation of iron overload through hepcidin level and its related factors in myelodysplastic syndromes.
Gu S; Song X; Zhao Y; Guo J; Fei C; Xu F; Wu L; Zhang X; Zhao J; Chang C; Li X
Hematology; 2013 Sep; 18(5):286-94. PubMed ID: 23540794
[TBL] [Abstract][Full Text] [Related]
4. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome.
Zipperer E; Post JG; Herkert M; Kündgen A; Fox F; Haas R; Gattermann N; Germing U
Ann Hematol; 2013 Dec; 92(12):1617-23. PubMed ID: 23842708
[TBL] [Abstract][Full Text] [Related]
5. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Park S; Kosmider O; Maloisel F; Drenou B; Chapuis N; Lefebvre T; Karim Z; Puy H; Alary AS; Ducamp S; Verdier F; Bouilloux C; Rousseau A; Jacob MC; Debliquis A; Charpentier A; Gyan E; Anglaret B; Leyronnas C; Corm S; Slama B; Cheze S; Laribi K; Amé S; Rose C; Lachenal F; Toma A; Pica GM; Carre M; Garban F; Mariette C; Cahn JY; Meunier M; Herault O; Fenaux P; Wagner-Ballon O; Bardet V; Dreyfus F; Fontenay M
Haematologica; 2019 Mar; 104(3):497-504. PubMed ID: 30287621
[TBL] [Abstract][Full Text] [Related]
6. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.
Cui R; Gale RP; Zhu G; Xu Z; Qin T; Zhang Y; Huang G; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
Leuk Res; 2014 May; 38(5):545-50. PubMed ID: 24598841
[TBL] [Abstract][Full Text] [Related]
7. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.
de Swart L; Reiniers C; Bagguley T; van Marrewijk C; Bowen D; Hellström-Lindberg E; Tatic A; Symeonidis A; Huls G; Cermak J; van de Loosdrecht AA; Garelius H; Culligan D; Macheta M; Spanoudakis M; Panagiotidis P; Krejci M; Blijlevens N; Langemeijer S; Droste J; Swinkels DW; Smith A; de Witte T;
Haematologica; 2018 Jan; 103(1):69-79. PubMed ID: 29122992
[TBL] [Abstract][Full Text] [Related]
8. Serum prohepcidin level in myelodysplasia.
El Husseiny NM; Matter MM; Sabry RM; Amin IS
Scand J Clin Lab Invest; 2010 Sep; 70(5):343-6. PubMed ID: 20509758
[TBL] [Abstract][Full Text] [Related]
9. Iron overload in myelodysplastic syndromes.
Mahesh S; Ginzburg Y; Verma A
Leuk Lymphoma; 2008 Mar; 49(3):427-38. PubMed ID: 18297518
[TBL] [Abstract][Full Text] [Related]
10. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
11. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.
Armand P; Kim HT; Rhodes J; Sainvil MM; Cutler C; Ho VT; Koreth J; Alyea EP; Hearsey D; Neufeld EJ; Fleming MD; Steen H; Anderson D; Kwong RY; Soiffer RJ; Antin JH
Biol Blood Marrow Transplant; 2011 Jun; 17(6):852-60. PubMed ID: 20854920
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
[TBL] [Abstract][Full Text] [Related]
13. Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes.
Hlaváčková A; Štikarová J; Pimková K; Chrastinová L; Májek P; Kotlín R; Čermák J; Suttnar J; Dyr JE
Free Radic Biol Med; 2017 Jul; 108():1-7. PubMed ID: 28300669
[TBL] [Abstract][Full Text] [Related]
14. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1.
Ambaglio I; Malcovati L; Papaemmanuil E; Laarakkers CM; Della Porta MG; Gallì A; Da Vià MC; Bono E; Ubezio M; Travaglino E; Albertini R; Campbell PJ; Swinkels DW; Cazzola M
Haematologica; 2013 Mar; 98(3):420-3. PubMed ID: 23300182
[TBL] [Abstract][Full Text] [Related]
15. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
Ghoti H; Fibach E; Westerman M; Gordana O; Ganz T; Rachmilewitz EA
Br J Haematol; 2011 Apr; 153(1):118-20. PubMed ID: 21332711
[TBL] [Abstract][Full Text] [Related]
16. Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome.
de Montalembert M; Ribeil JA; Brousse V; Guerci-Bresler A; Stamatoullas A; Vannier JP; Dumesnil C; Lahary A; Touati M; Bouabdallah K; Cavazzana M; Chauzit E; Baptiste A; Lefebvre T; Puy H; Elie C; Karim Z; Ernst O; Rose C
PLoS One; 2017; 12(3):e0172147. PubMed ID: 28257476
[TBL] [Abstract][Full Text] [Related]
17. Reduced serum hepcidin levels in patients with chronic hepatitis C.
Girelli D; Pasino M; Goodnough JB; Nemeth E; Guido M; Castagna A; Busti F; Campostrini N; Martinelli N; Vantini I; Corrocher R; Ganz T; Fattovich G
J Hepatol; 2009 Nov; 51(5):845-52. PubMed ID: 19729219
[TBL] [Abstract][Full Text] [Related]
18. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
19. Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis.
Arnold J; Sangwaiya A; Bhatkal B; Geoghegan F; Busbridge M
Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):425-9. PubMed ID: 19262400
[TBL] [Abstract][Full Text] [Related]
20. Serum tryptase measurements in patients with myelodysplastic syndromes.
Sperr WR; Stehberger B; Wimazal F; Baghestanian M; Schwartz LB; Kundi M; Semper H; Jordan JH; Chott A; Drach J; Jäger U; Geissler K; Greschniok A; Horny HP; Lechner K; Valent P
Leuk Lymphoma; 2002 May; 43(5):1097-105. PubMed ID: 12148892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
